Dosing and Toxicity: Managing Adverse Events of Single-Agent ICIs in Endometrial Cancer
March 13th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Bhavana Pothuri, MD, MS, discussed with participants their experiences managing adverse events of immunotherapy for advanced endometrial cancer.
Burns Compares Therapies Approved for NSCLC With an EGFR Exon 20 Insertion Mutation
March 12th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Timothy F. Burns, MD, PhD, discussed the trials supporting the use of mobocertinib and amivantamab for patients with non–small cell lung cancer and an EGFR exon 20 insertion.
Poll: How Would You Treat a Patient With NSCLC and an EGFR Exon 20 Insertion Mutation?
March 8th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Joel Neal, MD, PhD, discussed what options physicians would choose when treating a patient with non–small cell lung cancer who tested positive for an EGFR exon 20 insertion.
Campbell Discusses Choices for Patients With Favorable- and Intermediate-Risk RCC
March 8th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Matthew T. Campbell, MD, MS, discussed data supporting frontline combination therapies for patients with favorable- and intermediate-risk clear cell renal cell carcinoma.
Roundtable Discussion: Ailawadhi Compares Therapies in Newly Diagnosed Multiple Myeloma
March 7th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Sikander Ailawadhi, MD, discussed with participants the choice of regimen for a patient with transplant-eligible newly diagnosed multiple myeloma.
Managing Sacituzumab AEs and Looking Forward to Next-Line TNBC Therapy
March 6th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Hope S. Rugo, MD, discussed adverse event management in patients treated with sacituzumab govitecan for triple-negative breast cancer and other therapy options. This is the second of 2 articles based on this event.
PAOLA-1 Shows Benefit from Olaparib After Bevacizumab in Ovarian Cancer
March 1st 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Paul D. DiSilvestro, MD, discussed the updated results of the PAOLA-1 trial of bevacizumab followed by olaparib maintenance in patients with advanced ovarian cancer. This is the third of 3 articles based on this event.
Determining Need for Biopsy in Suspected Hepatocellular Carcinoma
February 27th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Daneng Li, MD, discussed what role a biopsy and other procedures might serve in a patient with a LI-RADS 5 liver lesion. This is the first of 2 articles based on this event.
Roundtable Discussion: Voss Looks at Integrating New Approaches in Clear Cell RCC Treatment
February 27th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Martin H. Voss, MD, discussed with participants their goals and approaches when considering third-line therapy for patients with advanced clear cell renal cell carcinoma.
Biology Informs Treatment Options for Steroid-Refractory Chronic GVHD
February 22nd 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Noah M. Merin, MD, PhD, discussed biologic phases of chronic graft-vs-host disease and which therapies are available for patients who do not respond to steroids.
Managing Adverse Events of Sacituzumab Govitecan in TNBC
February 20th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Hope S. Rugo, MD, discussed with participants the management of neutropenia and other toxicities associated with the antibody-drug conjugate sacituzumab govitecan in patients with metastatic triple-negative breast cancer.
Opinions on the Optimal Role of Ipilimumab/Nivolumab in RCC
February 13th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Alan Tan, MD, discussed with participants their experiences with frontline regimens for advanced renal cell carcinoma, and potential trials that could optimize the use of immunotherapy and tyrosine kinase inhibitors. This is the second of 2 articles based on this event.
Niraparib Maintenance Shows Continued PFS Improvement in Ovarian Cancer
February 9th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Paul DiSilvestro, MD, discussed the results of the PRIMA trial of niraparib maintenance therapy for patients with advanced ovarian cancer. This is the second of 3 articles based on this event.